Abstract
E has utility for mAb-mediated immune agonism therapies that are dependent on FcγRIIb interaction and of anti-inflammatory mAbs in allergy and autoimmunity that harness FcγRIIb inhibitory signaling.
Chenoweth AM, Esparon S, Wines BD, Schuurman J, Labrijn AF, Hogarth PM
VIEW FULL ARTICLEJournal Immunology and cell biology
Published 28 Apr 2023
Volume 101
ISSUE 7
Pagination 657-662
DOI 10.1111/imcb.12646
E has utility for mAb-mediated immune agonism therapies that are dependent on FcγRIIb interaction and of anti-inflammatory mAbs in allergy and autoimmunity that harness FcγRIIb inhibitory signaling.